{
    "clinical_study": {
        "@rank": "13193", 
        "arm_group": [
            {
                "arm_group_label": "Subjects with moderate chronic hepatic impairment", 
                "arm_group_type": "Experimental", 
                "description": "Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight"
            }, 
            {
                "arm_group_label": "Healthy subjects matched to moderate hepatic impaired subjects", 
                "arm_group_type": "Experimental", 
                "description": "Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight"
            }, 
            {
                "arm_group_label": "Subjects with mild chronic hepatic impairment", 
                "arm_group_type": "Experimental", 
                "description": "Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight"
            }, 
            {
                "arm_group_label": "Healthy subjects matched to mild hepatic impaired subjects", 
                "arm_group_type": "Experimental", 
                "description": "Single IV bolus of NO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight"
            }, 
            {
                "arm_group_label": "Subjects with severe chronic hepatic impairment", 
                "arm_group_type": "Experimental", 
                "description": "Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate and compare the pharmacokinetics and safety of ONO-2745/CNS 7056 in subjects\n      with the hepatic impairment and matched healthy subjects."
        }, 
        "brief_title": "An Open-label, Single-dose, Intravenous Administration Study of ONO-2745/CNS 7056 in Subjects With Chronic Hepatic Impairment", 
        "condition": [
            "Hepatic Impairment", 
            "Healthy"
        ], 
        "condition_browse": {
            "mesh_term": "Liver Diseases"
        }, 
        "detailed_description": {
            "textblock": "In Part One, 8 subjects with moderate hepatic impairment (Child Pugh Scale B) and 8 matched\n      healthy subjects will be enrolled.  In Part 2, 8 subjects with mild hepatic impairment\n      (Child-Pugh Scale A) and 8 matched healthy subjects will be enrolled.  In Part 3, 3 subjects\n      with severe hepatic impairment (Child-Pugh Scale C) will be enrolled.  Parts 2 and 3 will\n      only be initiated if the criteria per protocol is met in Part One.  The pharmacokinetics and\n      safety profiles will be compared between hepatic impaired subjects and healthy subjects."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males or females between 18 and 65 years of age\n\n          -  Negative test for the selected drugs of abuse at screening\n\n        Hepatic impaired subjects:\n\n          -  Stable hepatic function and medication regimen for at least 28 days prior  to\n             check-in\n\n          -  Degree of hepatic impairment will be determined by the Child-Pugh Scale\n\n        Exclusion Criteria:\n\n          -  Clinical manifestation of any disease (except hepatic impaired subjects)\n\n          -  History of significant hypersensitivity, intolerance, or allergy to any drug\n             compound, including food, or other substance"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01790607", 
            "org_study_id": "ONO-2745IVU007"
        }, 
        "intervention": {
            "arm_group_label": [
                "Subjects with moderate chronic hepatic impairment", 
                "Healthy subjects matched to moderate hepatic impaired subjects", 
                "Subjects with mild chronic hepatic impairment", 
                "Healthy subjects matched to mild hepatic impaired subjects", 
                "Subjects with severe chronic hepatic impairment"
            ], 
            "intervention_name": "ONO-2745 /CNS 7056", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Adult healthy subjects will be matched with individual subjects by age (\u00b1 5 years, gender, and BMI (\u00b1 15%)", 
        "lastchanged_date": "December 2, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Anaheim", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92803"
                    }, 
                    "name": "Anaheim Clinical Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32803"
                    }, 
                    "name": "Orlando Clinical Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "South Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33034"
                    }, 
                    "name": "South Miami Clinical Site"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "5", 
        "official_title": "An Open-label, Single-dose,Intravenous Administration Study to Compare the Pharmacokinetics and Safety of ONO-2745/CNS 7056 in Subjects With Chronic Hepatic Impairment With Matching Healthy Subjects", 
        "overall_official": {
            "affiliation": "Ono Pharmaceutical Co. Ltd", 
            "last_name": "Ono Pharma USA, Inc.", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "To study the effect of hepatic impairment on the pharmacokinetics of ONO-2745/CNS 7045 by assessment of drug concentration through blood sample analysis", 
                "safety_issue": "No", 
                "time_frame": "PK:  Pre-dose to 4 hours post-dose"
            }, 
            {
                "measure": "To study the effect of ONO-2745/CNS 7045 on the subjects with hepatic impairment by evaluating the safety parameters per protocol including labs, vitals and adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Overall safety: Pre-dose to 7 days post-dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01790607"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Ono Pharmaceutical Co. Ltd", 
        "sponsors": {
            "collaborator": {
                "agency": "Ono Pharmaceutical Co. Ltd", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Ono Pharma USA Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}